These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 20201744)

  • 1. Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall.
    Mattsson N; Blennow K; Zetterberg H
    Clin Chem Lab Med; 2010 May; 48(5):603-7. PubMed ID: 20201744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.
    Kang JH; Vanderstichele H; Trojanowski JQ; Shaw LM
    Methods; 2012 Apr; 56(4):484-93. PubMed ID: 22503777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.
    Mattsson N; Zetterberg H; Hansson O; Andreasen N; Parnetti L; Jonsson M; Herukka SK; van der Flier WM; Blankenstein MA; Ewers M; Rich K; Kaiser E; Verbeek M; Tsolaki M; Mulugeta E; Rosén E; Aarsland D; Visser PJ; Schröder J; Marcusson J; de Leon M; Hampel H; Scheltens P; Pirttilä T; Wallin A; Jönhagen ME; Minthon L; Winblad B; Blennow K
    JAMA; 2009 Jul; 302(4):385-93. PubMed ID: 19622817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-analytical and analytical factors influencing Alzheimer's disease cerebrospinal fluid biomarker variability.
    Fourier A; Portelius E; Zetterberg H; Blennow K; Quadrio I; Perret-Liaudet A
    Clin Chim Acta; 2015 Sep; 449():9-15. PubMed ID: 26141614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alzheimer's disease--Recent biomarker developments in relation to updated diagnostic criteria.
    Höglund K; Fourier A; Perret-Liaudet A; Zetterberg H; Blennow K; Portelius E
    Clin Chim Acta; 2015 Sep; 449():3-8. PubMed ID: 25668231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers.
    Mattsson N; Andreasson U; Persson S; Arai H; Batish SD; Bernardini S; Bocchio-Chiavetto L; Blankenstein MA; Carrillo MC; Chalbot S; Coart E; Chiasserini D; Cutler N; Dahlfors G; Duller S; Fagan AM; Forlenza O; Frisoni GB; Galasko D; Galimberti D; Hampel H; Handberg A; Heneka MT; Herskovits AZ; Herukka SK; Holtzman DM; Humpel C; Hyman BT; Iqbal K; Jucker M; Kaeser SA; Kaiser E; Kapaki E; Kidd D; Klivenyi P; Knudsen CS; Kummer MP; Lui J; Lladó A; Lewczuk P; Li QX; Martins R; Masters C; McAuliffe J; Mercken M; Moghekar A; Molinuevo JL; Montine TJ; Nowatzke W; O'Brien R; Otto M; Paraskevas GP; Parnetti L; Petersen RC; Prvulovic D; de Reus HP; Rissman RA; Scarpini E; Stefani A; Soininen H; Schröder J; Shaw LM; Skinningsrud A; Skrogstad B; Spreer A; Talib L; Teunissen C; Trojanowski JQ; Tumani H; Umek RM; Van Broeck B; Vanderstichele H; Vecsei L; Verbeek MM; Windisch M; Zhang J; Zetterberg H; Blennow K
    Alzheimers Dement; 2011 Jul; 7(4):386-395.e6. PubMed ID: 21784349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. International quality control survey of neurochemical dementia diagnostics.
    Lewczuk P; Beck G; Ganslandt O; Esselmann H; Deisenhammer F; Regeniter A; Petereit HF; Tumani H; Gerritzen A; Oschmann P; Schröder J; Schönknecht P; Zimmermann K; Hampel H; Bürger K; Otto M; Haustein S; Herzog K; Dannenberg R; Wurster U; Bibl M; Maler JM; Reubach U; Kornhuber J; Wiltfang J
    Neurosci Lett; 2006 Nov; 409(1):1-4. PubMed ID: 17045397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CSF biomarker variability in the Alzheimer's Association quality control program.
    Mattsson N; Andreasson U; Persson S; Carrillo MC; Collins S; Chalbot S; Cutler N; Dufour-Rainfray D; Fagan AM; Heegaard NH; Robin Hsiung GY; Hyman B; Iqbal K; Kaeser SA; Lachno DR; Lleó A; Lewczuk P; Molinuevo JL; Parchi P; Regeniter A; Rissman RA; Rosenmann H; Sancesario G; Schröder J; Shaw LM; Teunissen CE; Trojanowski JQ; Vanderstichele H; Vandijck M; Verbeek MM; Zetterberg H; Blennow K;
    Alzheimers Dement; 2013 May; 9(3):251-61. PubMed ID: 23622690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal fluid biomarkers for Alzheimer's disease.
    Blennow K; Zetterberg H
    J Alzheimers Dis; 2009; 18(2):413-7. PubMed ID: 19661632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Supportive CSF biomarker evidence to enhance the National Institute on Aging-Alzheimer's Association criteria for diagnosis of Alzheimer's type dementia--a study from Southern India.
    Huded CB; Bharath S; Chandra SR; Sivakumar PT; Varghese M; Subramanian S
    Asian J Psychiatr; 2015 Feb; 13():44-7. PubMed ID: 25468261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Batch prepared protein standards for cerebrospinal fluid (CSF) biomarkers for neurodegeneration.
    Petzold A; Verwey NA; van Uffelen K; Blankenstein MA; Teunissen C
    J Neurosci Methods; 2010 Nov; 193(2):296-9. PubMed ID: 20832428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proficiency testing programs for Alzheimer's disease cerebrospinal fluid biomarkers.
    Mattsson N; Andreasson U; Carrillo MC; Persson S; Shaw LM; Zegers I; Zetterberg H; Blennow K
    Biomark Med; 2012 Aug; 6(4):401-7. PubMed ID: 22917142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different cerebrospinal fluid levels of Alzheimer-type biomarker Aβ42 between general paresis and asymptomatic neurosyphilis.
    Luo X; Shi H; Hou L; Zhong X; Chen X; Zhang Y; Zheng D; Tan Y; Hu G; Mu N; Chen J; Fang Y; He H; Ning Y
    Eur J Neurol; 2015 May; 22(5):853-8. PubMed ID: 25707998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease.
    Sunderland T; Linker G; Mirza N; Putnam KT; Friedman DL; Kimmel LH; Bergeson J; Manetti GJ; Zimmermann M; Tang B; Bartko JJ; Cohen RM
    JAMA; 2003 Apr 23-30; 289(16):2094-103. PubMed ID: 12709467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrospinal fluid biomarkers for Alzheimer's disease: more to come?
    Zetterberg H; Blennow K
    J Alzheimers Dis; 2013; 33 Suppl 1():S361-9. PubMed ID: 22710917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Clinical Use of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease Diagnosis: The Italian Selfie.
    Sancesario GM; Toniolo S; Chiasserini D; Di Santo SG; Zegeer J; Bernardi G; ; Musicco M; ; Caltagirone C; Parnetti L; Bernardini S
    J Alzheimers Dis; 2017; 55(4):1659-1666. PubMed ID: 27911328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid β42.
    Mattsson N; Zegers I; Andreasson U; Bjerke M; Blankenstein MA; Bowser R; Carrillo MC; Gobom J; Heath T; Jenkins R; Jeromin A; Kaplow J; Kidd D; Laterza OF; Lockhart A; Lunn MP; Martone RL; Mills K; Pannee J; Ratcliffe M; Shaw LM; Simon AJ; Soares H; Teunissen CE; Verbeek MM; Umek RM; Vanderstichele H; Zetterberg H; Blennow K; Portelius E
    Biomark Med; 2012 Aug; 6(4):409-17. PubMed ID: 22917143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia.
    Skillbäck T; Farahmand BY; Rosén C; Mattsson N; Nägga K; Kilander L; Religa D; Wimo A; Winblad B; Schott JM; Blennow K; Eriksdotter M; Zetterberg H
    Brain; 2015 Sep; 138(Pt 9):2716-31. PubMed ID: 26133663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid β and tau.
    Hansson O; Batrla R; Brix B; Carrillo MC; Corradini V; Edelmayer RM; Esquivel RN; Hall C; Lawson J; Bastard NL; Molinuevo JL; Nisenbaum LK; Rutz S; Salamone SJ; Teunissen CE; Traynham C; Umek RM; Vanderstichele H; Vandijck M; Wahl S; Weber CJ; Zetterberg H; Blennow K
    Alzheimers Dement; 2021 Sep; 17(9):1575-1582. PubMed ID: 33788410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analytical aspects of molecular Alzheimer's disease biomarkers.
    Andreasson U; Vanmechelen E; Shaw LM; Zetterberg H; Vanderstichele H
    Biomark Med; 2012 Aug; 6(4):377-89. PubMed ID: 22917140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.